- Docket No.
- 3:23-cv-00019
- District Court
- Virginia
Goal
- Declaration that all or part of FDA's mifepristone REMS are unconstitutional
- Declaration that all or part of FDA's mifepristone REMS violate the APA
- Declaration that approval of mifepristone is lawful and valid
- Enjoin defendants from implementing mifepristone REMS
Issues
Litigation Content
Why this Matters:
The Plaintiffs allege that the Food and Drug Administration (FDA) violated the Equal Protection Clause of the U.S. Constitution and the Administrative Procedure Act by subjecting mifepristone to burdensome requirements that makes the drug extremely difficult to access and prescribe. Ensuring that individuals have access to safe and effective medication abortions enables patients to receive necessary reproductive health care.
Potential Impact:
Unnecessary restrictions on safe and effective drugs can create obstacles for doctors to promote medically appropriate care and jeopardize the health and safety of patients seeking medication for abortion services.
10 Major Filings
- JOINT STATUS REPORT (Jul 12, 2024)
- ORDER STAYING CASE (Jan 1, 2024)
- ORDER (Aug 21, 2023)
- MEMORANDUM OPINION (Aug 21, 2023)
- PLAINTIFFS’ SURREPLY IN SUPPORT OF PLAINTIFFS’ MOTION FOR PRELIMINARY INJUNCTION (Jul 7, 2023)
- COMBINED SUPPLEMENTAL MEMORANDUM IN OPPOSITION TO PLAINTIFFS’MOTION FOR PRELIMINARY INJUNCTION AND REPLY (Jun 30, 2023)
- COMBINED MEMORANDUM IN OPPOSITION TO PLAINTIFFS’ MOTION FOR PRELIMINARY INJUNCTION AND IN SUPPORT OF MOTION TO STAY (Jun 5, 2023)
- MEMORANDUM OF LAW IN SUPPORT OF PLAINTIFFS’ MOTION FOR PRELIMINARY INJUNCTION (May 8, 2023)
- PLAINTIFFS’ MOTION FOR PRELIMINARY INJUNCTION (May 8, 2023)
- COMPLAINT (May 8, 2023)